Compare stocks

IMMX vs TAOX

Immix Biopharma, Inc. Common Stock and Tao Synergies Inc. Common Stock

Compare the businesses

Immix Biopharma, Inc. Common Stock

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Open IMMX dashboard ↗

Tao Synergies Inc. Common Stock

TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.

Open TAOX dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗